Open AccessRegeneration of a Pediatric Alveolar Cleft Model Using Three-Dimensionally Printed Bioceramic Scaffolds and Osteogenic Agents: Comparison of Dipyridamole and rhBMP-2
Author(s) -
Christopher D. Lopez,
Paulo G. Coelho,
Lukasz Witek,
Andrea Torroni,
Michael I. Greenberg,
Dean L. Cuadrado,
Audrey M. Guarino,
Jonathan M. Bekisz,
Bruce N. Cronstein,
Roberto L. Flores
Publication year - 2019
Publication title -
plastic and reconstructive surgery/psef cd journals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.841
H-Index - 179
eISSN - 1076-5751
pISSN - 0032-1052
DOI - 10.1097/prs.0000000000005840
Subject(s) - dipyridamole , medicine , bioceramic , surgery , materials science , nanotechnology
Alveolar clefts are traditionally treated with secondary bone grafting, but this is associated with morbidity and graft resorption. Although recombinant human bone morphogenetic protein-2 (rhBMP-2) is under investigation for alveolar cleft repair, safety concerns remain. Dipyridamole is an adenosine receptor indirect agonist with known osteogenic potential. This study compared dipyridamole to rhBMP-2 at alveolar cleft defects delivered using bioceramic scaffolds.